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HWEAbstract Background: The Renin-Angiotensin System (RAS) is an important regulator for blood
pressure and kidney disease. The level of vaso active peptide Angiotensin-II is mainly determined by
the RAS enzyme angiotensin converting enzyme-1 (ACE-1).
Aim: To investigate the association of ACE I/D polymorphism and Chronic Kidney Disease
(CKD) in south India.
Methods: In the present study, we have collected CKD patients (n= 147) and control subjects
(n= 211) from Tamilnadu. Genotyping was carried out by polymerase chain reaction (PCR) on the
basis of allele specific primers.
Results: The DD genotype is associated with the female population (OR-CI = 2.40 (1.05–5.51),
p= 0.04) as compared to the male population (OR-CI = 0.75 (0.37–1.51), p= 0.42). Further, we
found the over representation of ‘‘I’’ – allele (homozygous II and heterozygous ID) in unaffected
males [OR (CI) – 0.58 (0.32–1.04), p= 0.07] which suggests its protective role in male population.
Conclusion: The DD genotype of ACE is associated with CKD in south India.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Chronic Kidney Disease (CKD) is an International public
health problem which is encompassing large phenotypes. Each
phenotype is the combination of an underlying kidney disease
and superimposing environmental and genetic factors. The
CKD is a polyphonic and complex disorder which results from
Table 1 Basic characteristics (mean, standard deviation) of
study sample.
Cases (n= 147) Controls (n= 211)
Male 100 130
Female 47 81
Age (years), male 53.9 ± 12.3 43.7 ± 14.1
Age (years), female 54.4 ± 10.4 43.9 ± 13.5
N: sample size.
30 S. Nagamani et al.gene–gene and gene–environmental interactions. The disease
pathogenesis of renal failure is well correlated with genetic
variability [1]; these findings highlight the importance of renal
disease and its complications. Hypertension and CKD are
closely associated diseases [2] which show several clinical
complications like elevated blood pressure, poor renal out-
come via pressure natriuresis mechanism [3,4]. Hypertension
and diabetes are the major causes for CKD and it is common
among different populations viz. African American, Hispanic,
Asian American and Indian [5,6]. The CKD has also been
observed very commonly among female population when
compared to male population [7,8].
The Renin-Angiotensin System (RAS) is a key regulator of
blood pressure and kidney function. The contribution of the
RAS system for hypertension is well documented but the role
of RAS in CKD still remains unclear. However, different types
of RAS blockers i.e. both angiotensin converting enzyme
(ACE) inhibitors and angiotensin receptor blockers have been
suggested to CKD patients in order to prevent severe kidney
damage [9]. Treatment with RAS inhibitors have been differed
for major inter individual differences and still it is questionable
to predict responders based on known pathophysiological
characteristics [10]. Thus, different polymorphisms in RAS
components are the major factors to contribute for its
heterogeneous association among CKD patients [11].
In RAS pathway angiotensin converting enzyme-1 (ACE-1)
is an important enzyme which determined the vasoactive pep-
tide Angiotensin-II. The plasma and tissue ACE levels may
also be determined by ACE insertion/deletion polymorphism.
Insertion (I) or deletion (D) of a 287 bp fragment in the 16th
intron of ACE gene is mainly related to kidney problems
among the hypertensive patients [12]. Moreover, the D allele
has played a vital role in the failure of the renoprotective
action of ACE inhibitors [13,14].
The goal of the present study is to assess the role of ACE I/
D polymorphism in CKD patients of Tamilnadu population.
We explored the association between ACE I/D polymorphism
and CKD in Tamilnadu population between the age group of
30 and 70 years.
2. Subjects and methods
2.1. Study population
A total of 147 CKD patients and 211 control subjects were
included in this study. This work was started after the approval
of Institutional Ethics Committee. Blood samples (5 ml) were
collected from CKD patients and healthy volunteers between
the age group of 30–70 years from the clinics after obtaining
the informed consent form from the participants. All the cases
included in this study are under CKD stages (II–V) as diag-
nosed and identified by the nephrologists. Individuals with
normal kidney function with matched age, sex and location
were selected as controls. All the necessary clinical data and
family history were recorded in the questionnaire for all the
participants. All the participants belonged to the Dravidian
ancestry living in Tamilnadu, south Indian population. Con-
trol samples were also collected from the volunteers of same
ethnicity. Genomic DNA was extracted using modified Mill-
er’s protocol [15] and it was quantified spectrophotometrically
by OD260/OD280 ratio. Genotyping was carried out with theallele specific primers method. Primers 50GCCCTGCAGGTG
TCTGCAGCATGT-30 (sense primer) and 50GGATGGCTCT
CCCCGCCTTGTCTC-30 (antisense primer) produced 319
and 597-bp amplicons for D and I alleles, respectively. The
primers were 50-TGGGACCACAGCGCCCGCCACTAC-30
(sense primer) and 50-TCGCCAGCCCTCCCATGCCCAT
AA-30 (antisense primer). The reaction yields a 335-bp
amplicon only in the presence of an ‘I’ allele and no product
in samples homozygous for DD [16].
2.2. Statistical analysis
Chi-square statistics was used to compare the differences in
ACE genotype frequencies between case and control subjects.
The strength of the association between genotype frequencies
was calculated by the odds ratio (O) and 95% confidence inter-
val (CI). Statistically significant accepted value was p < 0.005.
Hardy–Weinberg equilibrium (HWE) was used to test the fre-
quencies of the marker alleles by allele counting method. All
the statistical calculations were carried out using PLINK
1.07 [17] and STATA 11.0.
3. Results
Association studies between genetic polymorphisms are hall-
mark for detecting the complex diseases. However, studying
the relationship between allele and genotype frequencies of
candidate genes in the affected and unaffected subjects to
understand the genetic etiology of complex human traits is
an efficient method for molecular dissection of the disease
pathogenesis. Based on these, we determined the possible asso-
ciation between ACE I/D polymorphism and CKD patients
among the south Indian subjects.
Among the patients (n= 147), 100 (68.02%) are males and
47 (31.98%) are females, whereas in control subjects 130
(61.61%) are males and 81 (38.39%) are females. The mean
age of patients is 53.8 ± 12.3 years for male patients and
54.40 ± 10.42 years for female patients. The mean age of
control subjects (n= 211) is 43.71 ± 14.17 years and
43.90 ± 13.57 respectively for males and females (Table 1).
Genotype distributions of ACE I/D polymorphism were
compatible with Hardy–Weinberg equilibrium (HWE) expec-
tation in cases and control subjects. D allele is more prevalent
in cases than controls among the allele/genotype frequency
distributions which are shown in Tables 2 and 3. I is the minor
allele and D is the major allele.
Genotype, allele frequencies and odds ratio were calculated
for the variants to test the association of ACE I/D gene
polymorphism with CKD. Results are reported in Table 3.
Table 4 Distribution of ACE I/D polymorphisms (dominant and recessive model) in patients and control subjects.
SNP Gender Model TEST Case (N= 147) Control (N= 211) OR 95% CI P-value
ACE I/D All II + ID Vs DD DOM 107/40 144/67 1.24 0.78–1.98 0.356
II Vs ID +DD REC 45/102 51/160 1.38 0.86–2.21 0.176
Male II + ID Vs DD DOM 66/34 100/30 0.58 0.32–1.04 0.070*
II Vs ID +DD REC 28/72 33/97 1.14 0.63–2.06 0.656
Female II + ID Vs DD DOM 35/12 47/34 2.11 0.96–4.65 0.062*
II Vs ID +DD REC 11/36 21/60 0.87 0.38–2.02 0.751
DOM: dominant model; REC: recessive model; N: sample size; OR: odds ratio; CI: confidence Interval; DOMmodel: when DD is present only,
it will cause diseases, REC model: when D is in homozygous or heterozygous it will cause diseases.
* P< 0.05: statistically significant.
Table 3 Distribution of genotype frequencies of RAS gene polymorphisms in patients and control subjects.
SNP Gender Genotype Case% (n= 147) Control% (n = 211) OR 95% CI P-value
ACE I/D All II 30.61 (45) 24.17 (51) Ref
ID 42.17 (62) 44.07 (93) 1.32 0.79–2.21 0.285
DD 27.21 (40) 31.75 (67) 1.48 0.84–2.59 0.172
Male II 28 (28) 25.38 (33) Ref
ID 38 (38) 51.53 (67) 1.50 0.79–2.84 0.219
DD 34 (34) 23.07 (30) 0.7487 0.37–1.51 0.420
Female II 23.40 (11) 25.93 (21) Ref
ID 51.06 (24) 32.10 (26) 0.75 0.37–1.51 0.420
DD 25.53 (12) 41.98 (34) 2.40 1.05–5.51 0.038*
N: sample size; OR: odds ratio; CI: confidence interval; Ref: reference.
* P< 0.05: statistically significant.
Table 2 Distribution of allele frequencies in cases and controls stratified gender wise.
SNP Gender Minor allele Freq. allele case Freq. allele control v2 OR 95% CI P-value
ACE I/D All I 0.52 0.46 2.09 1.25 0.72–2.22 0.15
Male 0.47 0.49 0.78 0.85 0.58–1.73 0.38
Female 0.49 0.42 1.17 1.33 0.76–2.32 0.28
v2: Chi-square with 1 degree of freedom; OR: odds ratio.
Role of ACE I/D polymorphism in CKD patients 313.1. ACE I/D polymorphism
We could not find a significant association for the ungrouped
data of ACE I/D polymorphism. However, when we segre-
gated into male and female population, we found that DD
homozygous has a significant effect among females. The distri-
bution of DD genotype did not differ significantly between
CKD patients and controls. Slight increase in the frequency
of DD (31.75%) homozygous was observed among patients
when compared to control subjects (27.21%) (Table 3). The
presence of ‘‘I’’ – allele carriers (homozygous DD and hetero-
zygous ID) in case and control subjects (Table 3) suggests its
protective role in male population. In Table 4, the distribution
of DD genotype is more dominant (both cases and controls)
when compared to ID and II genotype based on trend estima-
tion. This association was estimated as odds ratio 0.58 with
95% CI 0.32–1.04 for male population and as odds ratio
2.11 with 95% CI 0.96–4.65 for female population (Table 4).
We estimated the genetic power using the ACE I/D poly-
morphism as an example; an 80% power should have to detectthe linkage between CKD and D allele at type I error of 0.05
when the sample includes 147 cases and 211 controls. We also
performed post hoc exploratory analyses to examine the
relationships of the polymorphisms with cases and control
subjects. Genetic power estimation showed that 147 cases and
211 controls had >80% power to detect the linkage between
ACE I/D variant and CKD in the south Indian population.
4. Discussion
CKD is associated with many major cardiac and osteoporosis
complications [18]. It mainly affects older population
(>50 years) [19]. Therefore the mean age for male CKD sub-
jects is 53.90 ± 12.33 and for females is 54.40 ± 10.42 in our
study population. We could not find significant changes
among the studied population [OR (CI) = 1.25 (0.72–2.22),
p= 0.15]. This result was consistent with previous investiga-
tions in different parts of the world viz. UK [20], Denmark
[21], Germany [22] and Japan (v2 = 1.63, p = 0.44) [23]. ‘‘I’’
allele is the minor allele in our case with OR (CI) = 1.25
32 S. Nagamani et al.(0.72–2.22). This result was similar to the already reported in
Asian individuals [OR (CI) = 1.40 (1.23–1.59)] and Caucasian
individuals [OR (CI) = 1.12 (1.04–1.21)] [24].
We found that DD genotype is associated with female
patients. Similar observations were also reported in different
populations. In 2010, Mansoor et al., [25] have reported that
the ACE I/D polymorphism is associated with female popula-
tion [OR (CI) = 0.81 (0.52–1.26) and p value 0.35] rather than
male population [OR (CI) = 1.95 (0.99–3.85) and p value
0.05]. In another study by Pinon et al. [26] found that the
DD genotype is the risk factor for the development of renal
disease. Further, a meta-analysis from Lin et al. [24] stated that
the gender dependent effect of the ACE I/D polymorphism has
been observed very commonly among different populations.
Thus, we segregated to male and female populations and the
DD genotype was found to be the major risk determinants
of CKD among female (OR = 2.40) population. This result
was also supported by previous results from France [27] and
Mexican population [26]. Furthermore, recently our group
[28] reported that female is more prone to hypertension after
menopause in Tamilnadu population. Most of the females in
our studied population are post-menopausal women. Based
on these observations we hypothesized, the DD genotype is
associated with increased activity of the ACE and subsequent
CKD among female population.
Our study has few limitations: (i) The study was conducted
with low number of sample size. (ii) We included one kidney
center in our study; More CKD patients from different kidney
centers can be included for better interpretation for the role of
ACE I/D polymorphism or the progression of CKD. (iii) The
CKD has been caused by different diseases such as hyperten-
sion, diabetes and diabetic nephropathy. The heterogeneity
of the CKD is also one of the limitations in our study. More-
over there are no measurements available to calculate the ACE
levels in order to correlate with ACE I/D polymorphisms in
this study. However, the samples are from homogenous genetic
background, therefore they may not be affected by unmea-
sured confounding factors of population stratification.
In conclusion, DD genotype is significantly more prevalent
in the CKD females than in general Tamilnadu population,
suggesting the deteriorative effect of the genotype on CKD
progression in females only.References
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